Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Esperion Therapeutis.Inc. buy Bank of America Co.

Esperion Therapeutis.Inc.
Start price
€1.27
15.06.23 / 50%
Target price
€3.68
15.06.24
Performance (%)
111.30%
End price
€2.69
16.06.24
Summary
This prediction ended on 16.06.24 with a price of €2.69. The BUY prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc. saw massive gains of 111.30%. Bank_of_America_Co_ has 50% into this prediction

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.

AI-generated
Performance without dividends (%)
Name 1w 1m 1y 3y
Esperion Therapeutis.Inc. 0.000% 0.000% 72.793% 91.494%
iShares Core DAX® 2,57 % 5,33 % 8,27 % 63,86 %
iShares Nasdaq 100 4,86 % 0,45 % 27,08 % 86,27 %
iShares Nikkei 225® 5,59 % -0,59 % 48,55 % 78,35 %
iShares S&P 500 3,25 % 2,50 % 23,35 % 68,71 %

Comments by Bank_of_America_Co_ for this prediction

In the thread Esperion Therapeutis.Inc. diskutieren
Prediction Buy
Perf. (%) 111.30%
Target price 3.681
Change
Ends at 15.06.24

Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "buy" rating. They now have a $4.00 price target on the stock, up previously from $1.25.
Ratings data for ESPR provided by MarketBeat

Bank of America Co. 
0
Report Share
15.06.23
In the thread Trading Esperion Therapeutis.Inc.
Prediction Buy
Perf. (%) 111.30%
Target price 3.681
Change
Ends at 15.06.24

Die von Bank_of_America_Co_ gewählte maximale Laufzeit wurde überschritten

Bank of America Co. 
0
Report Share
16.06.24

Stopped prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc.

sell
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€2.36
20.06.24
€2.33
20.06.25
-60.00%
21.06.25

Bank of America Co. 
20.06.24 50%